GS
GMAB icon

GTS Securities’s Genmab GMAB Stock Holding History

GTS Securities’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$882K Buy
+32,116
New +$854K 0.02% 491
2025
Q3 		– Sell
-114,743
Closed -$2.37M – 1526
2025
Q2 		$2.37M Buy
+114,743
New +$2.36M 0.11% 150
2025
Q1 		– Sell
-74,356
Closed -$1.55M – 1362
2024
Q4 		$1.55M Buy
+74,356
New +$1.63M 0.08% 197
2024
Q1 		– Sell
-9,337
Closed -$297K – 4082
2023
Q4 		$297K Buy
+9,337
New +$293K ﹤0.01% 3211

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

GTS Securities's GMAB Position: Q2 2026 in Review

GTS Securities opened a new position in Genmab (GMAB) in Q2 2026: 32,116 shares worth $882K. The stake represents 0.02% of the portfolio and ranks #491 among its holdings. This is a return to the name: GTS Securities previously reported a position in GMAB as recently as Q2 2025.

GTS Securities first reported a position in GMAB in Q4 2023 and has held it in 4 quarters since. The position peaked at $2.37M in Q2 2025. 291 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • GTS Securities held 32,116 shares of Genmab worth $882K as of Q2 2026.
  • Genmab was a new GTS Securities position in Q2 2026.
  • Genmab made up 0.02% of GTS Securities's portfolio in Q2 2026, its #491 holding.
  • GTS Securities first reported a position in Genmab in Q4 2023 and has held it in 4 quarters since.
  • GTS Securities's Genmab position peaked at $2.37M in Q2 2025.
  • 291 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.